Skip to content

Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy

Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03596476
Acronym
PRIMER
Enrollment
330
Registered
2018-07-23
Start date
2021-05-03
Completion date
2027-05-03
Last updated
2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro-esophageal Reflux Disease

Keywords

Gastro-esophageal reflux, High resolution Impedance Manometry, Resistance to proton pump inhibitors (PPI)

Brief summary

Gastro-esophageal reflux disease (GERD) is defined as the reflux of gastric content into the esophagus that causes troublesome symptoms or complications. Nine to 30% of the population suffers from GERD-suggestive symptoms (heartburn, regurgitation, chest pain, chronic couch, sore throat). In the absence of warning signs, proton pump inhibitors (PPI) are prescribed as first-line treatment. However, 20 to 60% of patients are unsatisfied because of persistent symptoms when taking PPI. Causes of persistent symptoms are: erroneous diagnosis of GERD (up to 50% of PPI non-responders), rumination syndrome, excessive weakly acid reflux on PPI due to defective esophago-gastric junction or an excessive number of transient lower esophageal sphincter relaxations (main mechanism of GERD), poor acid secretion inhibition on PPI, and non-compliance to therapy. Complementary examinations are indicated to explain persistent GERD symptoms. Upper gastro-intestinal endoscopy is performed first to rule out an esophageal tumor and to identify erosive esophagitis, a specific sign of GERD. However, it is normal in up to 70% of symptomatic GERD patients. Direct detection of reflux episodes is then requested to confirm GERD. The gold standard for reflux detection is the ambulatory measurement of esophageal pH for 24 to 96 hours using a catheter (catheter-based pH-monitoring) or a capsule clipped into the esophagus (wireless pH-monitoring). Reflux episodes are defined as an esophageal pH \< 4. Another method of reflux detection is based on liquid and gas detection in the esophagus using pH-impedance monitoring. Recently the combination of impedance and esophageal pressure monitoring, called esophageal high resolution impedance manometry (HRIM) was introduced to simultaneously identify reflux episodes and their mechanisms. It has several advantages over esophageal pH measurement: shorter recording duration (1 or 2 hours post prandial) and identification of reflux mechanisms that might guide the choice of the best therapeutic option. Hypothesis: The 1-hour post prandial esophageal HRIM might be useful to diagnose GERD.

Interventions

PROCEDUREUpper gastrointestinal (GI) endoscopy

An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.

PROCEDUREWireless pH monitoring

Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).

PROCEDUREPost prandial esophageal High Resolution Impedance Manometry

Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.

PROCEDUREpH-impedance monitoring

24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient older than 18 years * Typical symptoms of GERD (heartburn, regurgitation) at least twice a week despite PPI therapy for at least one month. * Reflux Disease Questionnaire (RDQ) score off PPI \> 3 * Subject with health insurance

Exclusion criteria

* Previous esophago-gastric surgery, * Previous history of developing esophageal or gastric tumor, esophageal stricture, or esophageal varices * Pregnancy (assessment at V0) * Contraindication to general anesthesia, * Contraindications to the wireless capsule pH-monitoring: pacemakers, implantable cardiac defibrillator, * Contraindications to HRIM: inability to tolerate nasal intubation, significant bleeding disorders for which nasal intubation is contraindicated, known esophageal obstruction is preventing the passage of the HRIM probe. * Intolerance or allergy to one component of the test meal, * Intolerance or allergy to PPI, * Inability to give consent, * Mentally unbalanced patients, under supervision or guardianship * Decline to participate in the study, * Participation in another study at the same time

Design outcomes

Primary

MeasureTime frameDescription
Number of reflux episodes identified on the post prandial HRIM1 hour after the end of the mealThe diagnostic performance of the number of reflux episodes measured by 1-hour post prandial HRIM will be evaluated by estimating the Area Under the ROC Curve and its 95% confidence interval. The gold standard to define GERD will be based on esophageal pH measurements with capsule (GERD is defined as acid exposure time (AET; percentage of total time with esophageal pH \< 4) greater than 6% for at least one day on wireless pH monitoring).

Secondary

MeasureTime frameDescription
Reflux mechanisms defined on post prandial HRIM1 hour after the end of the mealDescription of the reflux mechanisms associated with reflux episodes: rumination, transient lower esophageal sphincter relaxation (TLESR), defective esophago-gastric junction (EGJ) or unknown.
Baseline impedance measured on post prandial HRIM1 hour after the end of the mealMeasure of baseline impedance on a period without swallow 3 and 5 cm above the proximal border of the esophago-gastric junction
Resting pressure of the esophago-gastric junction1 hourMeasure of the resting pressure of the esophago-gastric junction on a period without swallowing
Esophageal histology4 weeksPresence of eosinophils cells in the esophageal mucosa \> 15/hpf, dilated intercellular spaces, and/or papillar elongation
Acid exposure time measured on wireless pH-monitoring4 daysThe diagnosis of GERD based on pH-monitoring. The diagnosis of GERD is positive if acid exposure time (AET; percentage of total time with esophageal pH \< 4) is greater than 6% for at least one day on wireless pH monitoring. The diagnosis of GERD is negative (ie absence of GERD) if the AET is below 4% during the 4 days of wireless monitoring. In the other instance , the diagnosis of GERD is uncertain.
Normalization of the number of reflux episodes detected on 24-h pH-impedance monitoring performed on PPI1 dayThe number of reflux episodes is normalized if the total number of reflux episodes is \< 60 /24 h) on pH-impedance monitoring performed on PPI.
Normalization of the acid exposure time measured on 24-h pH-impedance monitoring performed on PPI1 dayThe esophageal acid exposure (AET) is normalized if it is below 4% on pH-impedance monitoring performed on PPI.
Patient's preference regarding the type of examination1 dayPercentage of patients who preferred the wireless pH capsule and percentage of patients who preferred HRIM.
Response to 4-week regimen of dose PPI4 weeksClinical response is defined as a Reflux Disease Questionnaire score on PPI ≤ 3 after 4-week treatment

Countries

France

Contacts

Primary ContactSabine ROMAN, MD
sabine.roman@chu-lyon.fr4 72 11 01 36

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026